Case Report: Metastatic pancreatic ductal adenocarcinoma initially masked by multiple gastroduodenal ulcers with apparent endoscopic healing: a diagnostic pitfall - Report - MDSpire

Case Report: Metastatic pancreatic ductal adenocarcinoma initially masked by multiple gastroduodenal ulcers with apparent endoscopic healing: a diagnostic pitfall

  • By

  • Conghua Song

  • Zhen Chen

  • Chaozhong Huang

  • Xiaomei Li

  • June 24, 2026

  • 0 min

Share

Diagnostic Challenge: Metastatic Pancreatic Ductal Adenocarcinoma Concealed by Multiple Gastroduodenal Ulcers

Background

Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced stage due to nonspecific early symptoms that can mimic benign gastrointestinal disorders. This case illustrates the diagnostic challenges posed by multifocal gastroduodenal ulcers that may obscure underlying malignancies.

Data Highlights

No numerical data or trial data available in the source material.

Key Findings

  • A 69-year-old man presented with intermittent epigastric discomfort and multiple gastroduodenal ulcers.
  • Initial biopsies showed only chronic inflammatory changes without dysplasia or malignancy.
  • Despite treatment with high-dose vonoprazan and apparent endoscopic healing, the etiology of the ulcers remained unexplained.
  • Progressively rising CA19-9 levels prompted further imaging, revealing a pancreatic tail mass with hepatic and peritoneal metastases.
  • Laparoscopic biopsy confirmed moderately differentiated adenocarcinoma of pancreatic origin.

Clinical Implications

This case underscores the importance of considering underlying malignancies in patients with unexplained multifocal ulcerative disease, even when endoscopic healing is observed. Clinicians should remain vigilant for persistent symptoms and laboratory abnormalities that may warrant further imaging.

Conclusion

The case highlights that apparent endoscopic resolution of gastroduodenal ulcers does not rule out serious underlying conditions such as metastatic PDAC.

Related Resources & Content

  1. Journal of Gastrointestinal Surgery, 2025 -- Case Study and Literature Review on Pancreatic Serous Cystadenocarcinoma
  2. Frontiers in Surgery, 2026 -- Case Report: Unexpected LAMS obstruction following successful EUS-BD in a patient with pancreatic carcinoma
  3. Frontiers in Oncology, 2026 -- Metachronous cholangiocarcinoma following pancreaticoduodenectomy and the potential role of a migrated pancreaticojejunal stent: a case report and review of the literature
  4. Journal of Gastrointestinal Surgery — Autoimmune Pancreatitis Presenting as a Focal Mass and Simulating Pancreatic Cancer with Main Pancreatic Duct Obstruction
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
  6. ACR Appropriateness Criteria® Screening, Locoregional Assessment, and Surveillance of Pancreatic Ductal Adenocarcinoma: 2025 Update
  7. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  8. NCCN GUIDELINES FOR PATIENTS ® 2025 Pancreatic Ca
  9. Recommendations | Pancreatic cancer in adults: diagnosis and management | Guidance | NICE
  10. ASGE | American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the diagnosis and management of solid pancreatic masses: summary and recommendations
  11. Endoscopic ultrasound-guided tissue sampling: European Society of Gastrointestinal Endoscopy (ESGE) Technical and Technology Review - PubMed
  12. Comparison of EUS-FNA and EUS-FNB for diagnosis of solid pancreatic mass lesions: a meta-analysis of prospective studies: Scandinavian Journal of Gastroenterology: Vol 59, No 8
  13. Bridging the Divide: From Universal Germline Testing Guidance to Real-World Implementation in Pancreatic Cancer Care | JCO Oncology Practice
  14. Metastatic Pancreatic Cancer: ASCO Guideline Update - PMC
  15. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer | New England Journal of Medicine
  16. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine | New England Journal of Medicine
  17. FDA approves irinotecan liposome for first-line treatment of metastatic pancreatic adenocarcinoma | FDA
  18. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial - PMC

Original Source(s)

Related Content